AbCellera Biologics (ABCL) AI Stock Analysis

• Market Cap: $1.31B
• Dividend Yield: N/A
• Average Volume (3M): 3.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 7.16%
• EPS Growth: 3.95%
• Country: US
• Employees: 596
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 299,335,050
• 10 Day Avg. Volume: 4,081,432
• 30 Day Avg. Volume: 3,343,592
• PEG Ratio: -0.68
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 29.91
• P/FCF Ratio: -4.61
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 31.84
• Enterprise Value/Gross Profit: 39.80
• Enterprise Value/Ebitda: -6.04
• 1Y Price Target: $6.67
• Price Target Upside: 47.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $3.50 ▼(-22.57% Downside)

AbCellera Biologics' overall stock score reflects significant financial challenges, with declining revenues and profitability issues being the most impactful factors. While technical indicators suggest potential for a rebound, the valuation remains unattractive due to ongoing losses. The earnings call and corporate events provide some positive outlook, particularly with strong liquidity and strategic partnerships, but near-term financial pressures remain a concern.

Positive Factors

Strong Liquidity Position

A strong liquidity position with $680 million available provides financial flexibility to invest in R&D and strategic initiatives, supporting long-term growth.

Strategic Partnerships

The agreement with Bruker Corporation provides $36 million upfront and future royalties, enhancing cash flow and securing ongoing revenue streams.

Transition to Clinical-Stage Biotech

Transitioning to a clinical-stage biotech with active trials indicates progress in product development, potentially leading to future revenue from successful therapies.

Negative Factors

Increased Net Loss

The increased net loss reflects ongoing financial challenges, which could strain resources and impact the company's ability to invest in growth initiatives.

Rising R&D Expenses

Rising R&D expenses, while necessary for growth, can pressure margins and profitability, requiring careful management to ensure sustainable financial health.

Stagnation in Partner-Initiated Programs

Stagnation in partner-initiated programs could limit future revenue growth, as success depends on advancing these collaborations to marketable products.

AbCellera Biologics Business Overview & Revenue Model

Company Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

How the Company Makes Money

AbCellera generates revenue primarily through its partnerships and collaborations with pharmaceutical companies, where it provides its antibody discovery services. The company typically enters into agreements that include upfront payments, research funding, and milestone payments based on the progress of drug development. Additionally, AbCellera may receive royalties on sales of products that result from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its partners' therapeutic candidates, along with ongoing research contracts and collaborations that can provide continuous income streams.

AbCellera Biologics Financial Statement Overview

Summary

AbCellera Biologics faces significant financial challenges, with declining revenues and profitability issues impacting its income statement. The balance sheet remains strong with low leverage, but cash flow struggles highlight operational inefficiencies. The company needs to focus on improving revenue stability and profitability to enhance its financial health.

Income Statement

AbCellera Biologics has experienced significant revenue volatility, with a notable decline in revenue from 2022 to 2025. The company is currently operating at a loss, with negative net profit and EBIT margins, indicating profitability challenges. However, there was a slight revenue growth in the TTM period, suggesting potential recovery.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio, indicating conservative leverage. However, the negative return on equity in recent periods highlights profitability issues. The equity ratio remains stable, suggesting a strong capital structure despite operational losses.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, reflecting cash management challenges. Despite this, the free cash flow to net income ratio is positive, indicating some efficiency in converting earnings to cash. The recent growth in free cash flow is a positive sign, but overall cash flow health remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.32M	28.83M	38.02M	485.42M	375.20M	233.16M
Gross Profit	28.27M	28.83M	38.02M	418.99M	329.69M	206.01M
EBITDA	-186.27M	-204.15M	-192.16M	260.17M	239.15M	169.62M
Net Income	-171.68M	-162.86M	-146.40M	158.52M	153.46M	118.92M
Balance Sheet
Total Assets	1.36B	1.36B	1.49B	1.54B	1.32B	1.01B
Cash, Cash Equivalents and Short-Term Investments	520.67M	625.61M	760.59M	886.49M	722.98M	594.12M
Total Debt	137.05M	65.36M	77.38M	82.26M	40.06M	6.78M
Total Liabilities	391.95M	304.47M	335.78M	307.63M	292.84M	175.03M
Stockholders Equity	964.04M	1.06B	1.15B	1.23B	1.03B	830.51M
Cash Flow
Free Cash Flow	-153.11M	-186.95M	-121.38M	204.70M	186.13M	8.02M
Operating Cash Flow	-104.55M	-108.56M	-43.88M	277.36M	244.58M	22.69M
Investing Cash Flow	48.31M	121.41M	-221.11M	-352.63M	-332.25M	-119.78M
Financing Cash Flow	14.11M	12.77M	10.36M	-1.63M	-3.89M	683.65M

AbCellera Biologics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABCL, the sentiment is Positive. The current price of 4.52 is above the 20-day moving average (MA) of 3.70, above the 50-day MA of 3.85, and above the 200-day MA of 3.78, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 71.59 is Negative, neither overbought nor oversold. The STOCH value of 89.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABCL.

AbCellera Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GPCR	65 Neutral	$4.16B	-18.99	-25.31%	―	―	-64.91%
DNTH	61 Neutral	$1.64B	-11.20	-28.57%	―	-42.64%	-39.78%
SNDX	55 Neutral	$1.83B	-5.73	-129.32%	―	597.19%	0.45%
RCUS	55 Neutral	$2.60B	-6.21	-68.13%	―	-8.75%	-8.79%
EWTX	55 Neutral	$2.64B	-15.30	-30.02%	―	―	-5.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABCL	49 Neutral	$1.31B	-7.84	-16.81%	―	7.16%	3.95%

AbCellera Biologics Corporate Events

AbCellera Secures Global Settlement and Patent License Deal

On December 18, 2025, AbCellera Biologics announced a global settlement and patent license agreement with Bruker Corporation that resolves all patent litigation between the two companies. Under the agreement, Bruker will pay AbCellera $36 million upfront and provide ongoing royalty payments on worldwide sales of Bruker’s Beacon Optofluidic platform products for the life of the licensed patents, strengthening AbCellera’s cash position and securing a continuing revenue stream tied to Bruker’s commercial success.

The most recent analyst rating on (ABCL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

AbCellera Appoints Dr. Stephen Quake to Board

On November 10, 2025, AbCellera Biologics announced the appointment of Dr. Stephen Quake to its Board of Directors, enhancing the company’s commitment to scientific excellence. Dr. Quake, a renowned scientist and entrepreneur, brings extensive expertise in fields such as genomics and molecular diagnostics, aligning with AbCellera’s strategic goals. Concurrently, Andrew Lo resigned from the board, having contributed significantly to the company’s business and strategy since 2021.

The most recent analyst rating on (ABCL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

AbCellera Biologics Reports Q3 2025 Financial Results

AbCellera Biologics reported its financial results for the third quarter of 2025, highlighting the start of activities at its new clinical manufacturing facility and substantial completion of platform investments. The company ended the quarter with $680 million in available liquidity, despite a net loss of $57.1 million. Key developments included the appointment of a new Chief Medical Officer and progress in Phase 1 clinical trials for its lead programs. The company also reported an increase in partner-initiated program starts and molecules advanced into the clinic, reflecting its strategic focus on expanding its pipeline.

The most recent analyst rating on (ABCL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.